Consider the following:
The cost of Bavencio, a new cancer drug approved in March, is approximately $ 156,000 per year per patient.
A new drug for muscular dystrophy was launched at the end of last year at an amazing price: $ 300,000 per year.
In 2016, the Food and Drug Administration (FDA) approved Tecentriq, a new treatment for bladder cancer that costs $ 12,500 a month, or $ 150,000 a year.
Even drugs that have been on the market for a long time are not immune: the cost of insulin tripled between 2002 and 2013, although there were no notable changes in the formula or the manufacturing process. And the EpiPen, a vital anti-allergy medicine, launched four decades ago, increased in price by 500% since 2007. Public outrage this past winter over its price ($ 609 for a two-pack of injectors) helped accelerate the arrival to the market for other less expensive generic medicines.